Phase 2 N=25 Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Progression-free Survival (PFS) — 3.9 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=143 Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Primary: Brief Pain Index - Item 5, Average Daily Pain Score (Range 0-10) Higher Values Indicate Worse Pain — 4.24; 4.41; 4.27 Average daily pain score — p=0.5695
Phase 2 N=204 To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca
Primary: Change of Corneal Fluorescein Staining of the Inferior Cornea Region. — -1.00; -0.78; -0.78 units on a scale (Likert)
Phase 2 N=834 A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
Migraine
Primary: Percentage of Participants Reporting Pain Freedom (PF) at 2 Hours Post-Dose — 8.9; 5.6; 14.8; 21.4 percentage of participants
Phase 2 N=173 Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine
Migraine
Primary: The Number of Treated Subjects Who Became Pain-free (International Headache Society Grade of 0 = no Pain) by Observation Time Point. — 12; 7 participants
Phase 2 N=301 A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
Asthma
Primary: Change in FEV1 — -0.40; 0.69; -0.59 percentage of change
Phase 2 N=45 Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Prostatic Neoplasms
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 41 Participants
Phase 2 N=575 Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants
Infections, Streptococcal
Primary: Number of Subjects With Any and Grade 3 Solicited General Symptoms and With Solicited General Symptoms Related to Vaccination - Primary Phase of the Study — 82; 76; 72…
Phase 2 N=153 Study of Daily Rifapentine for Pulmonary Tuberculosis
Tuberculosis
Primary: Percentage of Participants With Negative Lowenstein Jensen Cultures at Week 8 — 85; 94; 96 percentage of participants w/LJ cx con
Phase 2 N=326 A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Score at Day 85 — 5.78; 5.73; 5.91; 5.67 units on a scale — p=<0.001
Phase 2 N=5 Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
Kaposi's Sarcoma
Primary: Localization — 5 participants
Phase 2 N=20 Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
Epilepsy · Tuberous Sclerosis Complex
Primary: Reduction in Seizure Frequency — 60 percentage
Phase 2 N=64 Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
Multiple Myeloma · Stage I Multiple Myeloma · Stage II Multiple Myeloma
Primary: Maximum Tolerated Dose (Phase I) — 0; 0; 0; 3 participants
Phase 2 N=96 Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
Malignant Glioma · Recurrent Glioblastoma
Primary: Progression Free Survival (PFS) at 6 Months — 0.29; 0.23 Months — p=0.26
Phase 2 N=105 S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants